Skip to main content
European Commission logo print header

Oncolytic viruses for the treatment of pediatric brain tumors: An integrated clinical and lab approach

Project description

Development of combinatorial adenovirus-based immunotherapy for paediatric brain tumours

Diffuse intrinsic pontine gliomas are aggressive paediatric brain stem tumours with a median overall survival of 9–11 months. The disseminating nature and localisation of the tumour prevent surgical resection, and the standard treatment is radiotherapy, which slightly improves short-term survival. Results from murine model and human trials revealed that the intratumoural injection of the oncolytic virus Delta-24-RGD instigated an initial phase of oncolysis followed by an inflammatory response that resulted in tumour shrinkage. The EU-funded ViroPedTher project aims to develop additional steps to enhance the immune response in those tumours via different types of ligands activating the tumour-infiltrating lymphocytes. This combinatorial treatment approach will overcome tumour immunosuppression, resulting in a significant improvement in prognosis.

Objective

The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses with the capacity to elicit a therapeutic immune response in those tumors. Our research will use novel and relevant models to accomplish the experimental aims. We have previously worked with Delta-24-RGD (DNX-2401) a replication-competent adenovirus that has been translated to the clinical scenario. In 2017, the first clinical trial phase I with DNX-2401 for newly diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG; a lethal pediatric brain tumor) opened propelled by my team. Preliminary results from the first trials revealed that the intratumoral injection of the virus instigated an initial phase of oncolysis followed by a delayed inflammatory response that ultimately resulted in complete regression in a subset of the patients without associated toxicities. I hypothesized that enhancement of the immune component of the DNX-2401-based therapy will result in the complete regression of the vast majority of pediatric brain tumors. In our specific approach, we propose to understand the immune microenvironment of DIPGs and the response to viral therapy in the context of the trial. Moreover, that knowledge will leverage the design of Delta-24-based adenoviruses to recruit lymphocytes to the tumor with the competence of different type of ligands to activate the tumor infiltrating lymphocytes. I expect that this combinatorial innovative treatment will efficiently challenge the profound and inherent tumor immunosuppression and, in turn, will elicit a robust anti-tumor immune response resulting in the significant improvement of the prognosis and quality of life of patients with pediatric brain tumors. This project has the potential to produce a vertical advance in the field of pediatric oncology.

æ

Coordinator

UNIVERSIDAD DE NAVARRA
Net EU contribution
€ 2 000 000,00
Address
Campus universitario edificio central
31080 Pamplona
Spain

See on map

Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 0,00

Beneficiaries (1)